New perspective on GLP-1 long-acting formulation: Pegsbio (02565) CR059 selected for ADA LBA monthly dosing potential receives attention.

Peg-Bio (02565) has recently gained attention in the market with its core pipeline CR059 being selected for the Late Breaking Abstract (LBA) at the American Diabetes Association (ADA) Scientific Sessions, once again shining the spotlight on its circRNA-LNP technology platform. As an innovative pharmaceutical company focused on metabolic diseases, Peg-Bio's recent recognition is not only due to being selected for the LBA but also because of the super-long acting GLP-1 technology pathway represented by CR059, which is bringing new possibilities to the market. The competition in the GLP-1 receptor agonist market is becoming increasingly intense, and the super-long acting route is gaining more attention. According to Frost & Sullivan data, the global GLP-1 receptor agonist market has entered a period of explosive growth, with the market size expected to exceed $80 billion in 2024 and surpass $150 billion in 2030, maintaining a double-digit compound annual growth rate. China's market, as one of the fastest-growing regional markets globally, is expected to reach 120 billion RMB in size by 2030, becoming a core driving force for global market growth. However, with international giants like Novo Nordisk and Eli Lilly, as well as numerous domestic pharmaceutical companies intensively entering the traditional peptide-based GLP-1 race, the competition has entered a phase of homogeneity, leading to price wars. In this context, long-acting and convenient administration have become the core watershed of industry competition, as well as the key direction for pharmaceutical companies to build differentiation barriers and seize market opportunities. From once-daily to once-weekly administration, the frequency of GLP-1 drugs is continuously decreasing, with monthly or even quarterly super-long acting formulations becoming the current focus of research and development. CircRNA-LNP technology: A new attempt to break away from traditional GLP-1 long-acting strategies The core highlight of Peg-Bio's CR059 comes from its independently developed circRNA-LNP technology platform. This pathway is significantly different from traditional peptide-based GLP-1 drugs, leading many investors to view it as a new attempt in the field of long-acting drugs. The long-acting properties of traditional peptide-based GLP-1 drugs mainly rely on chemical modifications, such as fatty acid side chain conjugation, PEGylation, or Fc fusion, which have advanced administration frequency from daily to weekly. However, extending the dosing interval further poses significant challenges. In contrast, CR059 adopts a nucleic acid drug route: integrating the sequence encoding GLP-1 analogs into circular RNA (circRNA) and coupling it with lipid nanoparticle (LNP) delivery systems to achieve sustained drug expression in the body. In other words, it attempts to transform the drug's mode of action from "single injection, single effect" to "single injection, sustained expression for a period of time." It is precisely for this reason that CR059 is seen by the market as a more identifiable technology pathway in the super-long acting GLP-1 direction. According to Peg-Bio's announcement on March 6, 2026, the first human trial of CR059 yielded positive results, with continuous improvement in glycated hemoglobin and fasting blood sugar levels in subjects lasting four weeks after a single dose, a significant increase in the proportion of time spent in blood sugar control. In a spontaneous type 2 diabetes rhesus monkey model, the glucose-lowering effect lasted at least 8 weeks, and the metabolic intervention effect was superior to mainstream long-acting GLP-1 drugs such as semaglutide. Additionally, CR059 incorporates artificial intelligence-assisted molecular design technology, optimizing GLP-1 analog sequences through algorithms to enhance receptor affinity while reducing immunogenicity, further improving the drug's safety and efficacy. Why is CR059 worth a closer look after being selected for ADA LBA? The American Diabetes Association (ADA) Scientific Sessions is an important academic conference in the field of diabetes and metabolic diseases globally, and a significant window for observing advanced research progress in the industry. As a highly anticipated segment, LBAs typically focus on newer and more discussed research results, hence being selected itself carries a certain screening significance. CR059 being selected for ADA's 2026 Scientific Sessions LBA signifies at least two points: first, the product's stage-specific data is deemed worthy of attention, and second, Peg-Bio's circRNA-LNP platform is beginning to gain broader international academic visibility. For a company still in the continuous validation phase of clinical and platform progression, such milestones are not only about being "seen" but also about attracting continued industry and capital market tracking more easily. However, being selected for LBA does not guarantee commercial success. The real determinants of a product's success still lie in the quality of subsequent clinical progression and data realization. But in terms of market rhythm, this milestone indeed makes CR059's subsequent clinical development more worthy of sustained attention. If the company successfully proceeds with the next research phase, further validates the safety and efficacy of monthly dosing, the product's potential for imagination is likely to continue to expand. From a single product to a pipeline ladder: What else is there to watch for Peg-Bio? In addition to CR059, Peg-Bio has already built a pipeline ladder covering seven investigational drugs, with a focus on metabolic diseases such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). The overall strategy is not just on betting on a single product but forming a combination of "commercialized products + clinical stage products + early-stage development projects." Among them, the company's commercialized product Pidacon (vemurafenib) is a fixed polyethylene glycol (PEG) modified peptide-based GLP-1 receptor agonist, administered weekly, with characteristics of low hypoglycemic occurrence rates and relatively mild gastrointestinal adverse reactions. It has been commercialized in the domestic market. In March 2026, Peg-Bio reached a strategic cooperation agreement with Tianjin Tengrui Pharmaceutical, granting the latter exclusive commercialization rights for Pidacon in mainland China. Peg-Bio will receive up to HK$140 million in equity proceeds and a double-digit percentage of sales revenue. This cooperation brings cash flow expectations to the company and helps expand product markets through Tianjin Tengrui Pharmaceutical's channel resources, indicating a practical significance for the company's future commercialization progress. In terms of clinical stage products, aside from CR059, PB-718, a dual-target receptor agonist activating both GLP-1 and GIP receptors, has entered phase II clinical trials, while PB-2301, a triple-target receptor agonist covering GLP-1/GIP/GCG receptors, is still in preclinical development. Looking at the entire metabolic disease landscape, such a pipeline layout implies that the company has more than one story to tell in the future and possesses a certain platform scalability. For its core pipeline CR059, Peg-Bio plans to adopt a "global layout + regional authorization" commercialization strategy: seek cooperation with international pharmaceutical companies in developed markets such as Europe, the US, and Japan to accelerate market penetration through mature channels; consider self-commercialization or partnership with local companies in China and emerging markets. This arrangement aligns with the common practices of most innovative pharmaceutical companies on flagship products. How does the market view Peg-Bio: Key lies in technological differentiation and realization pace Peg-Bio's recurring discussions in the market are primarily due to the differentiation brought by its circRNA-LNP technology platform and the potential for CR059 to gradually realize this differentiation. In March 2026, Peg-Bio was included in the Hong Kong Stock Connect, allowing mainland Chinese investors to trade directly, which is expected to improve stock liquidity and attract more attention from the financial sector. In terms of growth potential, according to Frost & Sullivan forecasts, the global market for super-long acting GLP-1 drugs (monthly dosing or higher) is poised to exceed $30 billion by 2030, with a compound annual growth rate of over 25%. If CR059 successfully progresses through clinical trials, reaches market approval, and leverages its differentiated technology pathway, it theoretically has the opportunity to stake a claim in this niche market. However, the ultimate valuation that the market is willing to ascribe still depends on whether the data, progress, and commercialization pace can gradually materialize. At the same time, it is important to note that the company faces multiple risks and challenges: although circRNA-LNP technology has made clinical progress, long-term safety and efficacy still need to be validated through large-scale clinical trials; international giants like Novo Nordisk and Eli Lilly are also entering the super-long acting GLP-1 market, potentially narrowing the gap with Peg-Bio through technology mergers or independent R&D efforts; the super-long acting GLP-1 market is still in the nurturing stage, and there is uncertainty in the acceptance of new dosing modes by doctors and patients, all of which could impact the development process. Overall, Peg-Bio's recent attention due to CR059's selection for ADA LBA is not only because it secured a seat at an academic conference but also because it has once again brought the company's technological pathway in the GLP-1 long-acting direction under the spotlight. For the market, being selected for LBA is a noteworthy milestone; for the company, the real factors that will determine its future space are clinical data, business development progress, and commercialization execution. In other words, Peg-Bio's story is far from over. How far will CR059 go in the future, how will Pidacon perform in sales, and whether platform capabilities can extend to more projects will all influence the market's judgment of the company. For investors interested in the innovative pharmaceutical direction of metabolic diseases, every step Peg-Bio takes next is still worth tracking.